Neuren Pharmaceuticals Profile

2.42
USD 0.01  0.41%
2.25Last Month High 2.62 
2.42Trading Day  High 2.42 

Neuren Pharmaceuticals Summary

Neuren Pharmaceuticals Limited (NURPF) is traded on OTC Market in USA. It is located in Camberwell, VIC and employs 10 people. The company currently falls under 'Small-Cap' category with current market capitalization of 253.27 M. Neuren Pharmaceuticals Limited has 92.1 M outstanding shares. NEUREN PHARMACEUT has accumulated about 998.66 K in cash with (5.93 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.01.
Check Neuren Pharmaceuticals Probability Of Bankruptcy

Neuren Pharmaceuticals Risk Profiles

Key Fundamentals

Neuren Pharmaceuticals Against Markets

Current Ratings

Neuren Pharmaceuticals 30 Days Performance Scores
Risk Adjusted
Performance Score (0 to 100)
4 
Chance of
Financial Distress (0 to 100%)
< 90% 
Equity ratings for Neuren Pharmaceuticals Limited are calculated dynamically based on Macroaxis scoring framework. Click here to learn more
Neuren Pharmaceuticals Limited, a biopharmaceutical company, focuses on the development of therapies for brain injury, neurodevelopment, and neurodegenerative disorders. more
NameNeuren Pharmaceuticals Limited
Macroaxis Advice
InstrumentUSA Stock Stocks Directory
Business AddressCamberwell, VIC
ExchangeOTC Market
BenchmarkDOW
Websitewww.neurenpharma.com
Contact Number61 3 9092 0480
CurrencyUSD - US Dollar

Did you try this?

Run Equity Forecasting Now
   

Equity Forecasting

Use basic forecasting models to generate price predictions and determine price momentum
Hide  View All  NextLaunch Equity Forecasting

Opportunities

Explore Investment Opportunities
Build portfolios using Macroaxis predefined set of investing ideas. Many of Macroaxis investing ideas can easily outperform a given market. Ideas can also be optimized per your risk profile before portfolio origination is invoked.
Explore Investing Ideas  

Executives

Neuren Pharmaceuticals Corporate Executives
Jon Pilcher CFO, Company Secretary
James Shaw COO